BCDA Stock Analysis: Buy, Sell, or Hold?
BCDA - BioCardia, Inc. Common Stock
$1.20
0.01 (0.84%)
▲
5d:
+10.09%
30d:
+33.3%
90d:
+3.45%
WAIT
LOW Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 10, 2026
Get Alerted When BCDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: BCDA is 17.6% above its trading range ($1.02). While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: BCDA is 17.6% above its trading range ($1.02). While momentum could continue, risk/reward favors waiting for a pullback.
In-depth Analysis How we analyze
Valuation Analysis: BCDA is currently trading at $1.20, which is considered extended relative to its 30-day fair value range of $0.85 to $1.02.
Technical Outlook: Technically, BCDA is in a downtrend. Immediate support is located at $0.87, while resistance sits at $1.26.
Market Sentiment: BCDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.50 (+1191.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BCDA is in a downtrend. Immediate support is located at $0.87, while resistance sits at $1.26.
Market Sentiment: BCDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $15.50 (+1191.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$0.85 -
$1.02
Company Quality Score
57/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
47.4%
All Signals
- BEARISH: Price significantly overextended (+17.6% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: Trading 1191.7% below Wall St target ($15.50)
- WARNING: Recommendation downgraded due to 17.6% overvaluation
Trading Range Analysis
30-Day Trading Range
$0.85 -
$1.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$0.87
Resistance Level
$1.26
Current Trend
Downtrend
Technical data as of
Jul 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.00
Wall Street Target
$15.50
(+1191.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: July 02, 2026 9:39 PM ET
Data refreshes hourly during market hours. Next update: 10:39 PM
Data refreshes hourly during market hours. Next update: 10:39 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BCDA showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Peter Altman
BUY
400 shares
2026-04-21
Peter Altman
BUY
600 shares
2026-04-20
Peter Altman
BUY
5000 shares
2026-02-04
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$257 | 61 BUY |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 62 BUY |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |